Demographic shifts and rapid advances in robotic therapy technology are propelling strong growth in the global rehabilitation robots market, which was valued at USD 393.2 million in 2023 and is projected to reach USD 1,429.6 million by 2031, expanding at a compound annual growth rate of 17.68%. As healthcare systems worldwide confront an aging population and rising rates of stroke and neurological disorders, robotic-assisted therapy is emerging as a scalable solution to growing rehabilitation demand.

Rehabilitation robots are assistive devices used in clinical settings to help patients recover motor skills, mobility, and strength through guided exercises and repetitive, precisely controlled motions. These systems are particularly effective for stroke recovery, neurological disorders, and musculoskeletal injuries, increasingly incorporating artificial intelligence and sensor technology to provide real-time feedback and adapt therapy intensity to individual patient progress.

Clinical Outcomes and Aging Populations Fuel Demand

The market’s primary growth driver is the demonstrated ability of robotic therapy to deliver measurable clinical improvements. By providing precise, repetitive therapy, these systems accelerate recovery and enhance outcomes in ways that make them increasingly attractive to healthcare providers seeking to improve patient care while managing costs.

Global demographic trends are reinforcing this momentum. Between 1974 and 2024, the global share of people aged 65 and older nearly doubled, from 5.5% to 10.3%, and United Nations projections indicate this figure will double again by 2074, reaching 20.7%, with the population aged 80 and above expected to more than triple. As age-related conditions such as stroke, arthritis, and neurodegenerative disease become more prevalent, rehabilitation robots are increasingly positioned as a cost-effective way to deliver targeted therapy that supports elderly patients’ mobility and independence.

Chronic Disease and Spinal Cord Injury Cases Add Momentum

Beyond aging demographics, the broader burden of chronic disease is reinforcing long-term demand. The World Health Organization reports that noncommunicable diseases account for 74% of global deaths annually, with cardiovascular disease alone responsible for 17.9 million deaths each year. Separately, the WHO estimates that more than 15 million people worldwide are affected by spinal cord injuries, primarily resulting from falls, road accidents, and trauma — a population increasingly reliant on advanced rehabilitation technologies, particularly exoskeleton systems, to regain functional independence.

Rehabilitation robots are also helping healthcare providers optimize resource allocation, enabling automated therapy that reduces dependence on constant human supervision and allows facilities to serve more patients without proportional increases in staffing costs. However, high upfront costs remain a genuine barrier to broader adoption, particularly in lower-resource settings. Companies are addressing this through production efficiencies, flexible leasing models, and partnerships with healthcare providers and government funding bodies aimed at improving affordability.

AI Integration and Home-Based Therapy Reshape the Market

Technological advancement in robotics and artificial intelligence continues to be a defining trend, with AI increasingly enabling real-time data analysis, personalized treatment planning, and continuous patient monitoring that improves therapy effectiveness. In November 2024, Lifeward (formerly ReWalk Robotics) unveiled a next-generation exoskeleton prototype developed under Israel’s national robotics innovation program, incorporating advanced sensing technology capable of autonomous decision-making — a signal of where the technology is heading over the coming years.

Simultaneously, the integration of rehabilitation robots into broader digital health ecosystems, including telemedicine and remote monitoring, is expanding accessibility beyond traditional clinical settings. This shift allows patients to receive therapy remotely, easing the burden on healthcare facilities while improving convenience — a trend reinforced by EIT Health’s backing of the ABLE Exoskeleton, which recently achieved CE Mark certification under new Medical Device Regulation standards for spinal cord injury rehabilitation following successful clinical trials in Germany and Spain.

Therapy Robots and Upper Body Applications Lead Segmentation

By type, therapy robots led the market in 2023 with a valuation of USD 150.5 million, reflecting their versatility across physical, occupational, and neurological rehabilitation applications and their particular value in supporting stroke and spinal cord injury recovery.

By application site, upper body rehabilitation captured the largest share at 56.90% in 2023, given its critical role in restoring essential daily functions such as feeding, mobility, and personal care for patients with neurological impairments. By end-user, rehabilitation centers are expected to grow at the fastest rate, expanding at a CAGR of 17.99%, owing to their infrastructure advantage in integrating sophisticated robotic technology and their capacity to manage high patient volumes.

North America Leads, Asia-Pacific Set for Fastest Growth

North America held the largest regional share in 2023, at approximately 38.02% of global revenue, worth USD 149.5 million, supported by advanced healthcare infrastructure and strong government funding for medical technology innovation. A November 2024 study by NewYork-Presbyterian found that nearly 65% of surveyed clinicians favored using robotic hand devices for both rehabilitation and daily household tasks, underscoring the growing clinical confidence in these systems across outpatient, acute, and subacute care settings.

Asia-Pacific is projected to be the fastest-growing region, expanding at a CAGR of 18.43% to reach approximately USD 352.3 million by 2031. Japan and South Korea are leading regional innovation in exoskeleton and AI-powered rehabilitation technology, while improving healthcare access across India, China, and Southeast Asia is expanding the addressable patient population for robotic rehabilitation solutions.

Competitive Landscape

Key players in the market include Kinova, Rex Bionics, BIONIK, Ekso Bionics, Lifeward, Siemens Healthineers, Hocoma, Bioxtreme, Rehab-Robotics Company, and CYBERDYNE, with competitive activity centered on partnerships and strategic acquisitions. In November 2024, CYBERDYNE partnered with the Japan International Cooperation Agency to supply robotic exoskeleton suits as part of an emergency recovery initiative in Ukraine, securing a USD 2.4 million order for 46 units — while Lifeward’s 2023 acquisition of AlterG expanded its portfolio into anti-gravity rehabilitation systems.

Outlook

As global populations continue to age and chronic disease prevalence climbs, rehabilitation robots are positioned to play an increasingly central role in healthcare delivery through 2031. Industry stakeholders expect continued advances in AI-driven personalization and home-based therapy models to further expand access, even as the industry works to address persistent cost barriers limiting adoption in resource-constrained settings.